orabase and Drug-Related-Side-Effects-and-Adverse-Reactions

orabase has been researched along with Drug-Related-Side-Effects-and-Adverse-Reactions* in 3 studies

Reviews

1 review(s) available for orabase and Drug-Related-Side-Effects-and-Adverse-Reactions

Article	Year
Evidence and hypotheses on adverse effects of the food additives carrageenan (E 407)/processed Eucheuma seaweed (E 407a) and carboxymethylcellulose (E 466) on the intestines: a scoping review. Critical reviews in toxicology, 2023, Volume: 53, Issue:9 This scoping review provides an overview of publications reporting adverse effects on the intestines of the food additives carrageenan (CGN) (E 407)/processed Eucheuma seaweed (PES) (E 407a) and carboxymethylcellulose (CMC) (E 466). It includes evidence from human, experimental mammal and Topics: Animals; Carboxymethylcellulose Sodium; Carrageenan; Drug-Related Side Effects and Adverse Reactions; Food Additives; Humans; Intestines; Mammals; Seaweed; Systematic Reviews as Topic	2023

Article

Year

Evidence and hypotheses on adverse effects of the food additives carrageenan (E 407)/processed Eucheuma seaweed (E 407a) and carboxymethylcellulose (E 466) on the intestines: a scoping review.

Critical reviews in toxicology, 2023, Volume: 53, Issue:9

This scoping review provides an overview of publications reporting adverse effects on the intestines of the food additives carrageenan (CGN) (E 407)/processed Eucheuma seaweed (PES) (E 407a) and carboxymethylcellulose (CMC) (E 466). It includes evidence from human, experimental mammal and

Topics: Animals; Carboxymethylcellulose Sodium; Carrageenan; Drug-Related Side Effects and Adverse Reactions; Food Additives; Humans; Intestines; Mammals; Seaweed; Systematic Reviews as Topic

2023

Trials

1 trial(s) available for orabase and Drug-Related-Side-Effects-and-Adverse-Reactions

Article	Year
Tacrolimus powder in Orabase 0.1% for the treatment of oral lichen planus and oral lichenoid lesions: an open clinical trial. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2006, Volume: 102, Issue:6 The aim of our study was to evaluate the clinical efficacy and safety profile of a novel compound, Tacrolimus powder in Orabase 0.1% in patients with LP and LL.. Seven patients with LP and 3 with LL were asked to participate. All patients received a 1 week treatment of Fluconazole, prior to entering the study, and on follow up visit were provided with a 15 g container of the study medication. Patients were asked to treat the most symptomatic site, three times a day for two weeks.. Disease control (signs) was achieved in most patients by the end of two weeks (from 1.58 to 0.55); all patients experienced a high degree of discomfort (pain) at baseline, which dropped quickly by the end of the second week of treatment (from 1.95 to 0.45); none developed yeast during the course of treatment. Recurrent headaches were reported by one patient with erosive LP, and transient burning by a patient with reticular LP.. Tacrolimus powder in Orabase 0.1% appears to have a relatively safe profile, and represents a likely alternative to topical steroids in the treatment of LP and LL, especially in those at risk for oral candidiasis. Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Carboxymethylcellulose Sodium; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunosuppressive Agents; Lichen Planus, Oral; Male; Middle Aged; Pain Measurement; Pharmaceutical Vehicles; Pilot Projects; Steroids; Tacrolimus; Treatment Outcome	2006

Article

Year

Tacrolimus powder in Orabase 0.1% for the treatment of oral lichen planus and oral lichenoid lesions: an open clinical trial.

Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2006, Volume: 102, Issue:6

The aim of our study was to evaluate the clinical efficacy and safety profile of a novel compound, Tacrolimus powder in Orabase 0.1% in patients with LP and LL.. Seven patients with LP and 3 with LL were asked to participate. All patients received a 1 week treatment of Fluconazole, prior to entering the study, and on follow up visit were provided with a 15 g container of the study medication. Patients were asked to treat the most symptomatic site, three times a day for two weeks.. Disease control (signs) was achieved in most patients by the end of two weeks (from 1.58 to 0.55); all patients experienced a high degree of discomfort (pain) at baseline, which dropped quickly by the end of the second week of treatment (from 1.95 to 0.45); none developed yeast during the course of treatment. Recurrent headaches were reported by one patient with erosive LP, and transient burning by a patient with reticular LP.. Tacrolimus powder in Orabase 0.1% appears to have a relatively safe profile, and represents a likely alternative to topical steroids in the treatment of LP and LL, especially in those at risk for oral candidiasis.

Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Carboxymethylcellulose Sodium; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunosuppressive Agents; Lichen Planus, Oral; Male; Middle Aged; Pain Measurement; Pharmaceutical Vehicles; Pilot Projects; Steroids; Tacrolimus; Treatment Outcome

2006

Other Studies

1 other study(ies) available for orabase and Drug-Related-Side-Effects-and-Adverse-Reactions

Article	Year
Drug induced xerostomia. The effects and treatment. Journal (Canadian Dental Association), 1985, Volume: 51, Issue:4 Topics: Carboxymethylcellulose Sodium; Dental Care; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Humans; Minerals; Mouthwashes; Saliva; Saliva, Artificial; Sodium Fluoride; Xerostomia	1985